about
Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma CellsRetrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project DatabaIdentification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots to in vitro assays using TOP15 charts.Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cellsIntrapleural bortezomib for the therapy of myelomatous pleural effusion: a case report.Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivoSuppression of viral gene expression in bovine leukemia virus-associated B-cell malignancy: interplay of epigenetic modifications leading to chromatin with a repressive histone code.Complete suppression of viral gene expression is associated with the onset and progression of lymphoid malignancy: observations in Bovine Leukemia Virus-infected sheepThe role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies.Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.Inhibition of Smad5 in human hematopoietic progenitors blocks erythroid differentiation induced by BMP4.Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes.Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.N-phosphonocarbonylpyrrolidine derivatives of guanine: a new class of bi-substrate inhibitors of human purine nucleoside phosphorylase.Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.TRAIL-induced apoptosis of HL60 leukemia cells: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFalpha but not to idarubicin and cytarabine.B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.[Malignant Lymphomas - Past, Present and Future].Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia.Hematopoiesis in patients with mature B-cell malignancies is deregulated even in patients with undetectable bone marrow involvement.The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms.Significantly higher numbers of proB cells in healthy Caucasians compared to Asians: Is there association with incidence of CLL?Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.Anaplastic Large-Cell Lymphoma Associated with Breast Implants: A Case Report of a Transgender Female.Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.[Staging and Treatment Response Evaluation in Malignant Lymphomas - Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification)].Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft modelReply to the letter to the editor by Guinn et alThe use of formalin-fixed, paraffin-embedded lymph node samples for the detection of minimal residual disease in mantle cell lymphomaAdvances in Molecular Biology and Targeted Therapy of Mantle Cell LymphomaCotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell LymphomaDrug Resistance in Non-Hodgkin LymphomasPotential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance
P50
Q28547322-020AFAFD-CE03-48FA-B32E-75CC01BCE17BQ30649483-B8132B3C-4778-414D-BE0E-89C96E6865F8Q33510964-9D37DD16-25EC-4711-A46C-A5E02C8C1E67Q33890300-5107099F-1A58-44A0-BD7A-3B9B0C494967Q34353406-3B6B545F-23C5-4B57-A872-6D3C935676F1Q34394503-EECE9E47-F9D1-4818-85A2-6E253CCAAF19Q34505392-E751335D-5573-4D7D-AC64-00D98F029469Q35857692-48396CF8-E338-42A0-9F6B-7E09D48C51D0Q35940048-5CBF7A9A-9E00-4FAF-AF4F-5F308EFC0ECCQ37705531-27908F72-6212-463C-BB7B-AA301531CFA9Q38047385-04E53076-3A6D-4F55-A1CA-0390A2617E49Q38288145-2385C323-64AE-4487-9F5E-62656E954C4EQ38716342-CFAA19F9-8135-4AAA-90EA-B62B47C3F5F2Q38820373-86960F37-72A8-4393-9FAC-E95FF0A9A1EEQ38827910-2BCBE106-9B4E-4F86-BE26-7CB277E30348Q38991388-362BF598-F417-4311-BCFE-81662862AB61Q39179567-4B679ED7-1824-4A4D-A30C-CD70ADDD65B1Q39308464-2B8AB708-637D-41CB-831F-8177E43CAC78Q39409021-082CD72B-9915-4C62-BCD0-7804C6AB7D42Q39608295-1A4C40EB-F71E-4DFB-A0E7-C0CFC1E77944Q39798588-4015829A-52C7-43E2-BE97-95C1C71940C3Q39911410-96E8E013-417C-4B2F-A305-B0846867C7B6Q40467460-491CB08F-9ACB-483E-81B0-035BD1AF3F07Q41196317-FBC4F25B-2E57-4D4B-BF1B-191074BFBB1CQ41387469-92CFDA85-D269-41E9-8F4B-3E480B54C0C1Q42361905-0DA7D841-C063-4879-8635-23068C25AC78Q43468001-3DAAF302-6372-4535-B0F1-C7F2514DCA9CQ43703857-EA3B2672-C013-4BB7-827F-D7FB672E084BQ45993077-D5DBD9E7-26DD-4713-A1BC-9D69FBC7C1FEQ47590529-7904F67D-4249-47FD-BB04-650B698BD4F8Q48105468-B2A40BFA-9E97-40E1-9805-EE0214B2D670Q49605090-063116C0-9B88-46DA-87B0-9C5C5CFE30C3Q51317074-BAD1C26B-BE29-4789-922B-AFCC4EB97FECQ60618110-474A2A3C-845B-457B-A388-0FE335AC3FF9Q84869316-55747D28-6FE2-4A9B-9262-60FE94A1468CQ85779439-76688C0C-D5BD-49BA-901A-0B31682CCC8EQ89996308-B84A502D-C50F-40D0-A1EA-646FC5824886Q90024410-A42FBD33-1044-4882-8720-D4B0F0DCDE2EQ90521649-B95A693C-2C43-4CB0-B836-E6813B94EAC7Q91056821-301FF0AA-535E-407D-A1D1-5CF3A61847D3
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pavel Klener
@ast
Pavel Klener
@en
Pavel Klener
@es
Pavel Klener
@nl
Pavel Klener
@sl
type
label
Pavel Klener
@ast
Pavel Klener
@en
Pavel Klener
@es
Pavel Klener
@nl
Pavel Klener
@sl
prefLabel
Pavel Klener
@ast
Pavel Klener
@en
Pavel Klener
@es
Pavel Klener
@nl
Pavel Klener
@sl
P1053
F-7185-2017
P106
P21
P31
P3829
P496
0000-0001-7786-9378